pdf1 Remedy (about 9.45%) has completed an inverted triple merger agreement with OptimizerX Post published:06/10/2019
pdf1 RMDY (about 6%) in merger agreement with OPTIMIZERX for cash and OPTIMIZERX shares, $ 1.1-3.7m Post published:08/09/2019
pdf1 External Investor Investments Closes $ 3 Million in Cleveland Diagnostics against Shares in Up to $ 6 Million Post published:02/09/2019
pdf1 The Company’s Board of Directors has approved a dividend distribution policy Post published:29/08/2019
pdf1 CD’X (about 7.85%) in understandings with investors investing $ 3m against shares in a round of up to $ 6m, reflecting a value of $ 65m Post published:12/08/2019
pdf1 CD’X (approximately 7.85%) – Promotes Trials for FDA Application for Prostate Cancer Diagnostic Product Post published:18/07/2019
